Subsequently, clinical studies demonstrated its efficacy in heart failure and chronic kidney disease30–32, and the indication was expanded; however, the mechanism of efficacy of SGLT2 inhibitors remains unclear. The gene discussed is SLC5A2; the disease is heart failure.